55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

Differential Diagnosis & Pathophysiology of Hypercalcemia

Calcium homeostasis is tightly orchestrated by the coordinated actions of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D ($1,25[OH]_2D$, calcitriol), and the calcium-sensing receptor (CaSR) across bone, kidneys, and the gastrointestinal tract. In clinical practice, more than 90% of all hypercalcemia cases are attributable to either Primary Hyperparathyroidism (PHPT) (the predominant etiology in ambulatory outpatients) or Malignancy (the predominant etiology in hospitalized, acutely ill patients).

Calcium Homeostasis & Laboratory Assessment

• Normal Serum Calcium Reference Range: Total serum calcium is normally 8.5 to 10.5 mg/dL (2.12 to 2.62 mmol/L); ionized calcium is 4.65 to 5.25 mg/dL (1.16 to 1.31 mmol/L).
• Albumin Correction Formula:
  • Approximately 40% to 45% of circulating calcium is bound to plasma proteins, predominantly albumin. In states of hypoalbuminemia, total serum calcium appears spuriously low while the physiologically active ionized calcium fraction remains normal.
  • Total calcium must always be adjusted using the standard correction equation: $\text{Corrected Calcium (mg/dL)} = \text{Measured Total Calcium (mg/dL)} + 0.8 \times [4.0 - \text{Serum Albumin (g/dL)}]$
  • Whenever diagnostic uncertainty persists, direct measurement of free ionized calcium using a heparinized whole-blood or serum sample is the definitive reference standard.

Physiological Actions of Parathyroid Hormone (PTH)

Secreted by parathyroid chief cells in response to hypocalcemia sensed by the cell-surface CaSR:

1. Bone: Binds to osteoblast receptors, upregulating RANK-ligand (RANKL) expression. RANKL binds RANK on osteoclast precursors, inducing osteoclast differentiation and activating osteoclastic bone resorption, releasing calcium and phosphate into circulation.
2. Kidney (Distal Convoluted Tubule): Stimulates active transcellular reabsorption of filtered calcium, decreasing renal calcium clearance.
3. Kidney (Proximal Convoluted Tubule):
   • Phosphaturic Action: Inhibits sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc), dramatically increasing urinary phosphate excretion and inducing hypophosphatemia.
   • 1-Alpha-Hydroxylase Activation: Upregulates the CYP27B1 enzyme, converting 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol).
4. Gastrointestinal Tract: Calcitriol acts on enterocytes to markedly stimulate active intestinal calcium and phosphate absorption.

Etiologic Differential Diagnosis of Hypercalcemia

                  DIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA

   Etiology                       Key Mechanism & Clinical Setting             PTH Level
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Primary Hyperparathyroidism    Autonomous parathyroid adenoma (85%)         Elevated or
   (PHPT)                         or hyperplasia (15%); asymptomatic outpatient Inappropriately Normal

   Malignancy: Humoral (HHM)      Tumor secretion of PTHrP (80% of cancer Ca)  Fully Suppressed
                                  (Squamous cell lung, head/neck, renal, uro)  (< 10-15 pg/mL)

   Malignancy: Osteolytic         Local cytokine osteolysis (multiple myeloma, Fully Suppressed
   Metastases                     breast cancer, extensive bone metastases)    (< 10-15 pg/mL)

   Malignancy / Granulomatous:    Autonomous extra-renal 1-alpha-hydroxylase   Fully Suppressed
   Calcitriol-Mediated            (Hodgkin/non-Hodgkin lymphoma, sarcoidosis)  (High 1,25[OH]2D)

   Familial Hypocalciuric         Inactivating CaSR gene mutation; lifelong    Normal or
   Hypercalcemia (FHH)            mild hypercalcemia; LOW urinary calcium      Mildly Elevated

   Medications: Thiazides         Reduces renal calcium clearance              Normal or Suppressed
   Medications: Lithium           Shifts CaSR set-point upward                 Normal or Mildly Elevated
   Milk-Alkali Syndrome           Calcium carbonate + alkali ingestion         Fully Suppressed
   Thyrotoxicosis                 Thyroid hormone-induced osteoclastosis       Fully Suppressed
   ═════════════════════════════════════════════════════════════════════════════════════════════

Primary Hyperparathyroidism vs. Familial Hypocalciuric Hypercalcemia (FHH)

Clinical Presentation of Primary Hyperparathyroidism (PHPT)

Primary hyperparathyroidism results from autonomous, unregulated parathyroid hormone secretion:

• Pathology: Solitary benign parathyroid adenoma (85% of cases), multiglandular four-vessel hyperplasia (15%; sporadic or familial as part of MEN1 or MEN2A), and parathyroid carcinoma (<1%; marked by severe calcium >14-15 mg/dL, palpable neck mass, and marked local tissue invasion).
• Symptomatic Spectrum: In modern clinical practice, >80% of patients with PHPT in North America are asymptomatic, discovered incidentally on routine automated biochemical panels. When symptomatic, manifestations follow the classic mnemonic "bones, stones, abdominal groans, and psychic moans":
  • Bones: Preferential demineralization of cortical bone over trabecular bone. The highest degree of bone mineral density loss occurs at the 33% (one-third) distal radius (which is 95% cortical bone), whereas the lumbar spine (predominantly trabecular bone) is relatively spared early in disease. In severe advanced untreated disease, osteitis fibrosa cystica develops (subperiosteal bone resorption of the phalanges, "salt-and-pepper" skull, bone cysts, and osteoclast-rich "brown tumors").
  • Stones: Recurrent nephrolithiasis (calcium oxalate and calcium phosphate stones) in 15% to 20% of patients; nephrocalcinosis.
  • Abdominal Groans: Constipation, anorexia, nausea, peptic ulcer disease (hypercalcemia stimulates gastric G-cells to hypersecrete gastrin and acid), and acute pancreatitis (calcium activates intrapancreatic trypsinogen).
  • Psychic Moans: Lethargy, depression, fatigue, cognitive slowing, memory impairment, sleep disturbances.
  • Cardiovascular: Hypertension, left ventricular hypertrophy, shortened QT interval on ECG.

Laboratory Profile in PHPT

• Serum Total and Ionized Calcium: Elevated (or fluctuating into the high-normal range in normocalcemic PHPT).
• Serum Intact PTH: Inappropriately elevated or "inappropriately normal". In the presence of hypercalcemia, normal physiological parathyroid feedback dictates that intact PTH should be suppressed to <10 to 15 pg/mL. An intact PTH level in the upper-normal or even mid-normal range (e.g., 45 pg/mL with a calcium of 11.2 mg/dL) represents autonomous, pathological hypersecretion and confirms the diagnosis!
• Serum Phosphate: Low or low-normal (<2.5 mg/dL) due to PTH-induced renal phosphaturia.
• Serum Chloride-to-Phosphate Ratio: A ratio > 33 strongly favors PHPT, reflecting distal renal tubular acidosis caused by PTH-induced bicarbonate wasting.
• Alkaline Phosphatase: Elevated in patients with high-turnover skeletal bone disease.
• 24-Hour Urinary Calcium: Typically elevated (>250-300 mg/day) due to the overwhelming filtered calcium load exceeding distal reabsorptive capacity.

Familial Hypocalciuric Hypercalcemia (FHH): The Great Mimicker

• Genetic Pathophysiology: Autosomal dominant loss-of-function inactivating mutation in the CASR gene on chromosome 3q (encoding the calcium-sensing receptor) or downstream G-protein signaling components (GNA11, AP2S1).
• The Blunted Calcium Set-Point: Parathyroid chief cells and renal tubular epithelial cells fail to properly sense circulating extracellular calcium. The set-point for calcium sensing is shifted to the right: the parathyroid requires a much higher calcium level to inhibit PTH secretion, and the renal thick ascending limb senses circulating calcium as abnormally low, driving avid, lifelong renal calcium reabsorption.
• Clinical Manifestations: Completely benign, lifelong, asymptomatic mild hypercalcemia. Patients DO NOT develop nephrolithiasis, fractures, bone loss, or renal insufficiency, and they have a normal life expectancy.
• CRITICAL CLINICAL PEARL: THE SURGICAL CONTRAINDICATION:
  • Parathyroidectomy is completely ineffective in FHH because the inactivating receptor mutation is present throughout all tissues. Surgical resection fails to normalize serum calcium and subjects the patient to lifelong iatrogenic hypoparathyroidism!
  • Patients with FHH must be identified to prevent unnecessary neck exploration.

The Diagnostic Discriminator: The CCCR Formula

Distinguishing PHPT from FHH requires calculating the 24-Hour Urine Calcium-to-Creatinine Clearance Ratio (CCCR) from a fasting 24-hour urine collection and concurrent serum chemistry:

                  CALCIUM-TO-CREATININE CLEARANCE RATIO (CCCR)

   CCCR = [ 24-Hour Urine Calcium (mg/dL) x Serum Creatinine (mg/dL) ] / 
          [ Serum Calcium (mg/dL) x 24-Hour Urine Creatinine (mg/dL) ]

   Diagnostic Cutoffs:
   ─────────────────────────────────────────────────────────────────────────────
   CCCR < 0.01          Highly suggestive of FAMILIAL HYPOCALCIURIC HYPERCALCEMIA (FHH)
                        (Sensitivity ~85%, Specificity ~88%)
                        • DO NOT OPERATE! Parathyroidectomy is contraindicated.
                        • Confirm with CASR gene genetic testing and family screening.

   CCCR > 0.02          Confirms PRIMARY HYPERPARATHYROIDISM (PHPT)
                        • High urinary calcium clearance; evaluate for surgical resection.

   CCCR 0.01 to 0.02    Indeterminate "Gray Zone"
                        • Coexisting severe Vitamin D deficiency in PHPT can falsely lower
                          urinary calcium into this range. Correct Vitamin D (replete 25-OH-D
                          to >30 ng/mL) and repeat 24-hour urine collection.
   ─────────────────────────────────────────────────────────────────────────────

Surgical Indications in Asymptomatic PHPT & Preoperative Localization

While parathyroidectomy is universally indicated for all patients with symptomatic PHPT (nephrolithiasis, fragility fractures, symptomatic hypercalcemia), the vast majority of patients are asymptomatic.

International Consensus Guidelines for Parathyroidectomy in Asymptomatic PHPT

The American Association of Endocrine Surgeons (AAES) and international consensus guidelines establish definitive criteria for surgical referral in asymptomatic patients. Meeting ANY ONE of the following criteria warrants parathyroidectomy:

                  GUIDELINE CRITERIA FOR PARATHYROIDECTOMY IN ASYMPTOMATIC PHPT

   Clinical Domain            Specific Threshold Criteria Indicating Surgery
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Serum Calcium              Serum total calcium > 1.0 mg/dL (> 0.25 mmol/L) above the upper limit
                              of normal (e.g., > 11.5 mg/dL if laboratory ULN is 10.5 mg/dL)

   Age                        Age < 50 years (patients face decades of progressive bone/renal loss)

   Skeletal Health            • Bone mineral density (DEXA) T-score <= -2.5 at lumbar spine, total
                                hip, femoral neck, or 33% (one-third) distal radius; OR
                              • History of a fragility fracture; OR
                              • Asymptomatic vertebral fracture on spine imaging (VFA or X-ray)

   Renal Health               • eGFR < 60 mL/min/1.73m² (without alternative explanation); OR
                              • 24-hour urinary calcium excretion > 400 mg/day (> 10 mmol/day)
                                WITH an increased stone-risk biochemical profile; OR
                              • Nephrolithiasis or nephrocalcinosis detected on abdominal imaging
                                (ultrasound, non-contrast CT, or plain radiograph)
   ═════════════════════════════════════════════════════════════════════════════════════════════

• Preoperative Localization Imaging vs. Diagnosis:
  • Preoperative localization studies (e.g., Technetium-99m Sestamibi SPECT/CT scan, high-resolution neck ultrasound, or 4D-CT) are performed solely to assist the endocrine surgeon in planning a targeted, minimally invasive parathyroidectomy versus bilateral neck exploration.
  • CRITICAL BOARD EXAM PEARL: Localization scans are NEVER used to diagnose hyperparathyroidism! A negative sestamibi or ultrasound scan does not exclude PHPT, nor does it disqualify a patient from surgical parathyroidectomy.
• Medical Management for Non-Surgical Candidates:
  • If surgery is refused or contraindicated: Ensure adequate oral hydration (2-3 liters/day); avoid thiazide diuretics and lithium; maintain moderate dietary calcium intake (do not restrict calcium, which drives compensatory PTH elevation); consider Cinacalcet (a calcimimetic that binds CaSR, suppressing PTH and normalizing serum calcium) or oral bisphosphonates (alendronate) to preserve skeletal bone density.

Malignancy-Associated Hypercalcemia & Acute Severe Hypercalcemic Crisis

Hypercalcemia of malignancy is the most common cause of hypercalcemia in hospitalized patients, carrying a grave prognosis (median survival 1 to 3 months). It develops via three distinct pathophysiological mechanisms:

                  MECHANISMS OF HYPERCALCEMIA OF MALIGNANCY

   Mechanism               Tumor Types & Biology                       Endocrine Laboratory Profile
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Humoral Hypercalcemia   Squamous cell carcinomas (lung, head/neck,  • Intact PTH fully suppressed (<10 pg/mL)
   of Malignancy (HHM)     esophagus, cervix); renal cell, bladder Ca; • Serum PTHrP markedly elevated
   (~80% of cancer cases)  Tumor secretes Parathyroid Hormone-Related  • Calcitriol (1,25[OH]2D) low/normal
                           Protein (PTHrP), binding PTH-1 receptors    • Serum phosphate low (phosphaturia)

   Osteolytic Bone         Multiple myeloma, breast cancer,            • Intact PTH fully suppressed (<10 pg/mL)
   Metastases              non-small cell lung cancer;                 • Serum PTHrP normal or low
   (~20% of cancer cases)  Tumor cells in marrow secrete local         • Calcitriol normal or low
                           cytokines (RANKL, IL-1, IL-6, TNF-alpha)    • Extensive bone lesions on imaging

   Calcitriol-Mediated     Hodgkin and Non-Hodgkin Lymphoma;           • Intact PTH fully suppressed (<10 pg/mL)
   Hypercalcemia           systemic granulomatous diseases             • Calcitriol (1,25[OH]2D) markedly elevated
   (<1% of cancer cases)   (Sarcoidosis, Tuberculosis, Berylliosis);   • 25-OH-Vitamin D normal
                           Autonomous 1-alpha-hydroxylase in macrophages • Serum phosphate normal/high
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Acute Severe Hypercalcemic Crisis: The Multimodal Emergency Protocol

Severe hypercalcemia is defined as a total serum calcium > 14.0 mg/dL (or ionized calcium >3.0 mmol/L), or moderate elevation (12.0-13.9 mg/dL) accompanied by acute altered mental status, severe dehydration, or cardiac dysrhythmias. High calcium activates CaSR in the medullary collecting duct, blunting ADH responsiveness and causing nephrogenic diabetes insipidus, profound polyuria, volume depletion, prerenal azotemia, and decreased calcium filtration, establishing a vicious cycle of accelerating hypercalcemia.

                  ACUTE SEVERE HYPERCALCEMIA EMERGENCY RESUSCITATION

   Therapeutic Modality           Mechanism, Dosing & Onset             Critical Clinical Pearls
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Step 1: Aggressive IV Isotonic Expands extracellular volume,        Infuse 200 to 300 mL/hr (titrated to
   0.9% Normal Saline (NaCl)      restores renal blood flow, promotes   cardiac/renal status). Lowers calcium
                                  urinary sodium and calcium excretion  by 1.5 to 2.0 mg/dL over first 24-48 hrs.

   Step 2: Subcutaneous or        Inhibits osteoclastic bone resorption Dose: 4 to 8 IU/kg SC or IM every 12 hrs.
   Intramuscular Calcitonin       and increases renal calcium excretion Rapid onset (2-4 hrs), but TACHYPHYLAXIS
                                                                        (receptor down-regulation) occurs at 48 hrs.

   Step 3: Intravenous            Potent pyrophosphate analogs; bind    Zoledronic Acid 4 mg IV over 15 min
   Bisphosphonates                hydroxyapatite, induce osteoclast     (or Pamidronate 60-90 mg IV over 2-4 hrs).
   (Zoledronic Acid)              apoptosis, stopping bone resorption   Delayed onset (takes 48-72 hrs to work),
                                                                        but prolonged duration (lasts 2-4 weeks).

   Alternative: Denosumab         Monoclonal antibody inhibiting RANKL; Dose: 120 mg SC weekly during induction.
   (Subcutaneous)                 blocks osteoclast maturation          Agent of choice for BISPHOSPHONATE-
                                                                        REFRACTORY hypercalcemia or eGFR <30.

   Targeted: Glucocorticoids      Inhibits macrophage 1-alpha-hydroxylase Prednisone 20-40 mg PO daily or IV
   (Prednisone / Hydrocortisone)  activity; reduces gut Ca absorption   hydrocortisone; indicated specifically for
                                                                        LYMPHOMA, SARCOIDOSIS, VITAMIN D TOX.

   LAST-LINE / RESTRICTED:        Inhibits loop of Henle calcium        NEVER GIVE FUROSEMIDE UNTIL VOLUME
   Loop Diuretics (Furosemide)    reabsorption                          STATUS IS COMPLETELY RESTORED!
                                                                        Reserved strictly for volume overload.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Pituitary Disorders: Prolactinomas, Acromegaly & Compressive Mass Effects

Pituitary adenomas are benign monoclonal neoplasms arising from adenohypophyseal corticotroph, lactotroph, somatotroph, thyrotroph, or gonadotroph cells, classified by size and functional hormone secretion.

Sellar Anatomy & Macroadenoma Compressive Mass Effects

The pituitary gland rests within the bony sella turcica, immediately inferior to the optic chiasm and flanked bilaterally by the cavernous sinuses (transmitting cranial nerves III, IV, $V_1$, $V_2$, and VI, and the internal carotid arteries):

• Microadenomas (< 10 mm in diameter): Confined to the sella turcica; do not compress adjacent neurovascular structures. Present exclusively with endocrine hypersecretion syndromes.
• Macroadenomas (>= 10 mm in diameter): Expand beyond the sella, producing characteristic compressive mass effects:
  • Bitemporal Hemianopsia: Suprasellar extension compresses the decussating nasal retinal nerve fibers in the central optic chiasm, producing selective loss of the peripheral temporal visual fields in both eyes.
  • Headache: Upward stretching of the pain-sensitive diaphragma sellae.
  • Cranial Nerve Palsies: Lateral invasion into the cavernous sinus impairs ocular motility (diplopia, ptosis; CN III palsy most common).
  • Hypopituitarism: Compression of normal surrounding non-adenomatous anterior pituitary tissue leads to sequential, progressive loss of pituitary hormones (classic order of loss: GH ──► LH/FSH ──► TSH ──► ACTH).
  • Pituitary Apoplexy: Acute, catastrophic ischemic infarction or hemorrhage into a preexisting macroadenoma, presenting with sudden-onset thunderclap headache, acute visual acuity collapse, ophthalmoplegia, and life-threatening adrenal crisis. Requires emergent high-dose IV hydrocortisone and urgent transsphenoidal neurosurgical decompression.

Prolactinoma (Lactotroph Adenoma): Most Common Functional Adenoma

Prolactinomas represent 40% to 50% of all pituitary adenomas. Prolactin secretion is uniquely subject to tonic, constitutive inhibition by hypothalamic dopamine acting on lactotroph D2 receptors.

                  PROLACTINOMA: CLINICAL PRESENTATION & DIAGNOSTIC WORKUP

   Demographic Group       Clinical Features                      Diagnostic Evaluation & Prolactin Levels
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Premenopausal Women     • Oligomenorrhea or amenorrhea        • Fasting morning serum prolactin
                           • Bilateral galactorrhea (breast milk) • Serum Prolactin > 200-250 ng/mL:
                           • Infertility (hyperprolactinemia        Virtually pathognomonic for prolactinoma
                             suppresses hypothalamic GnRH pulses) • Mild Prolactin Elevation (20-100 ng/mL):
                           • Early diagnosis (microadenomas)        Rule out secondary etiologies:
                                                                    - Drugs (antipsychotics, metoclopramide)
   Men & Postmenopausal    • Decreased libido, erectile dysfxn      - Primary Hypothyroidism (high TRH stimulates PRL)
   Women                   • Gynecomastia, oligospermia             - Stalk Effect (macroadenoma blocks dopamine)
                           • Late presentation with macroadenomas   - Chronic kidney disease, cirrhosis
                           • Visual loss (bitemporal hemianopsia) • Dedicated Pituitary MRI with Gadolinium
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

• Management: The Medical-First Paradigm:
  • Unlike virtually all other solid intracranial neoplasms, the first-line treatment for prolactinomas is MEDICAL THERAPY WITH DOPAMINE AGONISTS, NOT SURGERY!
  • Cabergoline (First-Line Choice):
    • Potent, long-acting D2 receptor agonist dosed once or twice weekly (0.25 to 1.0 mg twice weekly).
    • Normalizes serum prolactin in >85% to 90% of patients, restores gonadal function, and induces dramatic tumor shrinkage in >80% of microadenomas and macroadenomas, rapidly decompressing the optic chiasm and reversing visual field defects.
    • Substantially superior gastrointestinal tolerability (less nausea, vomiting, dizziness) and higher efficacy compared to bromocriptine.
  • Bromocriptine (Alternative): Short-acting daily oral dopamine agonist; historically preferred in women desiring immediate pregnancy due to extensive safety records, though cabergoline is widely used.
  • Indications for Transsphenoidal Surgery: Reserved strictly for prolactinomas refractory to high-dose dopamine agonists, patients intolerant of dopamine agonist psychiatric or cardiac valvular side effects, or tumors causing progressive visual loss despite medical therapy.

Acromegaly (Somatotroph Adenoma): Growth Hormone Excess

Acromegaly is caused by autonomous hypersecretion of Growth Hormone (GH) by a somatotroph adenoma (typically a macroadenoma at diagnosis due to an insidious 8- to 12-year diagnostic delay). (In pediatric patients before epiphyseal growth plate fusion, GH hypersecretion produces Gigantism).

• Pathophysiology & IGF-1 Biology:
  • Pituitary GH stimulates the liver to synthesize and release Insulin-Like Growth Factor 1 (IGF-1), which mediates peripheral somatic tissue hypertrophy, bone remodeling, and metabolic disruption.
  • Why Random GH is Useless: Circulating GH is secreted in pulsatile, episodic bursts with a plasma half-life of only 20 minutes, frequently dropping to undetectable levels in normal individuals and spiking under physical stress or fasting. A single random serum GH level is completely non-diagnostic.
  • In contrast, serum IGF-1 has a stable 15-hour half-life bound to IGF-binding protein 3 (IGFBP-3), providing an integrated biochemical measure of 24-hour GH exposure.
• Clinical Manifestations:
  • Acral & Soft Tissue Overgrowth: Progressive enlargement of the hands and feet (patients report increasing shoe, ring, and glove sizes); broadening of fingers ("spade-like" hands).
  • Craniofacial Changes: Coarsening of facial features, prominent frontal bossing, enlargement of the nose, thickening of lips, severe macroglossia (scalloped tongue), and prognathism (mandibular overgrowth resulting in underbite, malocclusion, and widening teeth spacing).
  • Cardiovascular Complications (Leading Cause of Mortality): Biventricular concentric hypertrophy, acromegalic cardiomyopathy, diastolic heart failure, accelerated coronary atherosclerosis, and secondary hypertension.
  • Metabolic & Respiratory: Severe obstructive sleep apnea (OSA) (present in >70% of patients due to pharyngeal soft tissue hypertrophy and macroglossia); insulin resistance, impaired fasting glucose, and secondary Type 2 Diabetes Mellitus (GH directly opposes insulin action, stimulating hepatic gluconeogenesis).
  • Oncologic Surveillance: Markedly increased incidence of adenomatous colonic polyps and colorectal cancer, warranting baseline screening colonoscopy at diagnosis and regular surveillance.
  • Musculoskeletal: Severe degenerative arthropathies, kyphoscoliosis, and carpal tunnel syndrome (bilateral median nerve compression from synovial thickening).

                  DIAGNOSTIC & THERAPEUTIC PROTOCOL FOR ACROMEGALY

   Step                        Procedure & Clinical Threshold Interpretation
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Step 1: Initial Screening   Measure Serum Insulin-Like Growth Factor 1 (IGF-1)
                               • Serum IGF-1 elevated above age- and sex-matched reference range
                                 confirms high suspicion of GH hypersecretion.

   Step 2: Confirmatory Test   Oral Glucose Tolerance Test (75g OGTT) with GH Measurement
                               • Physiological Response: Oral glucose load suppresses GH < 1.0 ng/mL
                                 (or < 0.4 ng/mL on ultrasensitive assays).
                               • Acromegaly Confirmed: FAILURE OF GH SUPPRESSION (<1.0 ng/mL)
                                 demonstrates autonomous, unregulated somatotroph secretion.

   Step 3: Imaging             Dedicated Pituitary MRI with Gadolinium
                               • Visualizes pituitary adenoma (macroadenoma in >75-80% of cases)
                                 and delineates cavernous sinus extension.

   First-Line Therapy:         Transsphenoidal Surgical Resection (TSS)
   Surgical Extirpation        • Unlike prolactinomas, SURGERY IS FIRST-LINE for acromegaly!
                               • Cures 70-85% of microadenomas and 40-50% of macroadenomas.

   Medical Therapy             Indicated for residual or unresectable disease following surgery:
   (Second-Line)               • Somatostatin Receptor Ligands (Octreotide LAR, Lanreotide): First-line
                                 medical therapy; inhibits GH release via SSTR2/SSTR5 receptors.
                               • GH Receptor Antagonist (Pegvisomant): Blocks peripheral IGF-1 synthesis.
                               • Dopamine Agonists (Cabergoline): Effective in tumors co-secreting prolactin.
   ═════════════════════════════════════════════════════════════════════════════════════════════